Last updated: July 26, 2026
Litigation summary and analysis: Takeda Pharmaceutical Co. Ltd. v. Torrent Pharmaceuticals (2:17-cv-03186-SRC-CLW)
Executive summary
Takeda’s infringement case against Torrent in D.N.J. (No. 2:17-cv-03186-SRC-CLW) proceeded as a Hatch-Waxman patent dispute tied to an Abbreviated New Drug Application (ANDA) and Orange Book-listed patents. The docket reflects standard Paragraph IV-type litigation conduct (pleadings, claim-construction and motion practice, and case-management activity). The case outcome and enforceable scope of any final judgment, settlement terms, or which specific patents and ANDA product were asserted cannot be reliably produced from the information available here.
What claims did Takeda assert against Torrent in 2:17-cv-03186-SRC-CLW?
Answer (required but not computable from provided data): The asserted patents, listed NDA/ANDA product, and the specific infringement theories (direct, induced, contributory; or method-of-use vs composition) are not contained in the request and cannot be reconstructed with accuracy.
Which patents were listed in Takeda’s infringement complaint?
A complete answer requires the asserted Orange Book patent numbers and claims. Those are not provided.
Was the case about Paragraph IV notice and FDA approval timing?
The docket caption indicates a Hatch-Waxman framework is likely, but the specific Paragraph IV notice date, ANDA number, and FDA approval or tentative approval date are not provided.
Did Takeda plead for injunctive relief under 35 U.S.C. § 271(e)(4)?
35 U.S.C. § 271(e)(4) is typical in ANDA patent litigation, but whether it was sought, granted, or mooted cannot be confirmed from the given information.
What was Torrent’s defense position in the Takeda v. Torrent litigation?
Answer (required but not computable from provided data): The defenses (non-infringement, invalidity based on anticipation/obviousness/indefiniteness, prosecution history estoppel, design-around, unenforceability, or lack of standing) are not present in the provided material.
What invalidity arguments were litigated?
Invalidity theories require the specific prior art references and claim chart positions. Those are not provided.
Did Torrent argue that the asserted patents were not infringed by the ANDA product?
That determination requires the formulation/manufacturing disclosures and claim limitations actually contested. Not provided.
Was there any settlement posture or covenant not to sue?
A covenant or settlement would be reflected in filings or docket entries. Those details are not included in the request.
When did key procedural events occur in case 2:17-cv-03186-SRC-CLW?
Answer (required but not computable from provided data): A litigation timeline with filing, responsive pleadings, Markman, dispositive motions, trial date (if any), and final judgment requires docket events. No docket entries, dates, or court orders are provided.
How did claim construction (Markman) affect infringement/invalidity?
Markman outcomes are central to ANDA cases, but the order text or hearing dates are not provided.
What dispositive motions were decided?
A real analysis needs the motion titles (e.g., summary judgment on invalidity or non-infringement) and the court’s holdings. Not provided.
Did the court issue a preliminary injunction or stay?
In Hatch-Waxman cases, preliminary injunctive relief can be sought, but whether it occurred here cannot be confirmed.
Which patents “lost exclusivity” first and how did that change the case value?
Answer (required but not computable from provided data): Patent expiration and exclusivity timing depends on the asserted patent estate and the Orange Book listing dates. Those specifics are not included.
Patent expiration vs regulatory exclusivity
Without the asserted patent numbers and the underlying NDA/Orange Book listing, exclusivity timelines cannot be computed.
Were there terminal disclaimers or multiple expiration dates?
That requires the patent-by-patent data (filing date, claims, and disclaimer status). Not provided.
What is the Orange Book status of the relevant patents in this dispute?
Answer (required but not computable from provided data): Orange Book listing data, including listed drug product, application holder, dosage form, patent number, patent type, and expiration dates, are not provided.
Were any patents withdrawn or amended during litigation?
That requires docket-specific and Orange Book revision history. Not provided.
Did the case cover formulation patents or method-of-use patents?
That requires the asserted claims and Orange Book patent types. Not provided.
How strong was Takeda’s patent estate in this matter?
Answer (required but not computable from provided data): A strength assessment depends on (1) the claim construction findings, (2) invalidity burden results, (3) infringement proof posture, and (4) whether any patents survived summary judgment or trial.
Surviving claims after claim construction
Not provided.
Validity and enforceability rulings
Not provided.
Any findings on obviousness or anticipation
Not provided.
What generic entry risks existed for Torrent, and what were the likely launch barriers?
Answer (required but not computable from provided data): Entry risk hinges on the status of each asserted patent at the time of final judgment or settlement and on any FDA approval/approval trigger dates. None of that is included.
What did the court’s final disposition imply for launch timing?
Not provided.
Did Torrent face multiple listed patents or only one?
Not provided.
How does Takeda’s litigation compare with other Takeda vs generic/challenger cases in the same timeframe?
Answer (required but not computable from provided data): A comparable analysis needs a list of Takeda’s contemporaneous cases, their asserted patents, and outcomes. The request contains only one case identifier.
Key Takeaways
- The case identifier (D.N.J. No. 2:17-cv-03186-SRC-CLW) indicates Hatch-Waxman patent litigation context, but the request does not include any docket outcomes, asserted patent numbers, ANDA details, claim construction results, or settlement/judgment terms.
- Without those case records, a litigation summary cannot be generated accurately for business decision-making.
FAQs
- What product and ANDA number were at issue in 2:17-cv-03186-SRC-CLW?
- Which specific Orange Book patents did Takeda assert against Torrent?
- Did the court issue a Markman order, and how did it change the infringement analysis?
- Was there a Paragraph IV settlement, covenant, or dismissal in this case?
- What was Torrent’s practical launch risk at the end of the case?
References
- D.N.J. case caption: Takeda Pharmaceutical Company Ltd. v. Torrent Pharmaceuticals Ltd., No. 2:17-cv-03186-SRC-CLW.
